UBS AG set a CHF 78 target price on Novartis AG (VTX:NOVN) in a research note published on Monday, August 28th, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.
NOVN has been the subject of a number of other reports. Deutsche Bank AG set a CHF 81 price target on shares of Novartis AG and gave the company a neutral rating in a report on Wednesday, July 19th. Morgan Stanley set a CHF 75 price target on shares of Novartis AG and gave the company a sell rating in a report on Monday, May 29th. Sanford C. Bernstein set a CHF 94 price target on shares of Novartis AG and gave the company a buy rating in a report on Tuesday, July 18th. J P Morgan Chase & Co set a CHF 70 price target on shares of Novartis AG and gave the company a neutral rating in a report on Saturday, May 20th. Finally, Kepler Capital Markets set a CHF 87 target price on shares of Novartis AG and gave the company a buy rating in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of CHF 85.
Novartis AG (VTX:NOVN) traded down 0.84% during midday trading on Monday, hitting CHK 82.40. The company had a trading volume of 15,085,035 shares. The stock has a 50 day moving average of CHK 81.19 and a 200 day moving average of CHK 78.54. The firm has a market cap of CHK 193.05 billion and a price-to-earnings ratio of 30.08. Novartis AG has a 52-week low of CHK 67.40 and a 52-week high of CHK 84.35.
TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/novartis-ag-novn-pt-set-at-chf-78-by-ubs-ag/1565479.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.